中文摘要：

目的进一步了解非胃黏膜相关淋巴组织（MALT）淋巴瘤患者的临床特点并探讨合理的治疗方法。方法回顾性分析57例经病理确诊的非胃MALT淋巴瘤患者资料，对其临床特点和治疗疗效进行分析。结果57例患者中，男32例、女25例，中位年龄58（14～86）岁，常见发病部位为肺及支气管（17例，29．8％）、肠道（16例，28．1％）、涎腺（8例，14．0％）、眼及附属器（7例，12．3％）等。临床分期为Ⅰ～Ⅱ期者35例（61．4％），Ⅲ-Ⅳ期者22例（38．6％），淋巴结受累者26例（45．6％），多个结外器官受累者7例（12．5％）。56例接受治疗的患者完全缓解率为66．0％，总反应率85．7％。中位随访时间52个月，患者5年总生存（0s）率和5年无疾病进展生存（PFS）率分别为91．6％和77．7％。单纯手术组、单纯化疗组、手术＋化疗、手术＋化疗＋放疗组5年Os率分别为87．5％、100．0％、90．2％和100．0％，5年PFS率分别为62．3％、80．0％、90．2％和75．O％，差异无统计学意义。单纯手术者复发率高（22．3％）。结论非胃MALT淋巴瘤起病呈播散性，患者治疗反应率高，预后好，各种治疗方法的0s率差异无统计学意义，但单纯手术者复发率高。

英文摘要：

Objective To further understand the clinical features of non-gastric mucosa-associated lymphoid tissue （MALT） lymphoma and investigate its suitable treatment. Methods A retrospective survey of 57 non-gastric MATL lymphoma patients pathologically confirmed in our hospital from 1999 to 2011. Results The median age was 58 years （range 14 -86 years）. Common presenting sites of non-gastric MALT lymphoma included lungs and upper respiratory tract （ 17 patients, 29.8% ） , intestinal tracts （ 16 patients, 28.1% ） , orbital and ocular adnexal（7 patients, 12.3% ） , and salivary glands （ 8 patients, 14.0% ）. Stage I - lI disease presented in 35 patients（61.4% ）, stage III- IV disease in 22 patients （38.6%）. A total of 26 patients had nodal involvement and 7 patients multiple organ involvement. Regimens included surgery alone, chemotherapy alone, surgery followed by chemotherapy or chemoradiotherapy. The complete response （CR） rate was 66.0% and the overall response rate 85.7%. At a median follow-up of 52 months, the 5-year overall survival （OS） and the 5-year progression free survival （PFS） were 91.6% and 77.7% , respectively. The 5-year survival rate of surgery, chemotherapy, surgery ＋ chemotherapy, surgery ＋ chemotherapy ＋ ra- diotherapy groups were 87.5% , 100.0% , 90.2% and 100.0% , respectively, without significant differences. The 5-year PFS of the four groups were 62.3%, 80.0%, 90.2% and 75.0% respectively. Conclu- sions Non-gastric MALT lymphoma is characterized by disseminated onset, favorable response to treatments and good outcomes. There is no statistically significant difference in the overall survival of the various treatments. But the recurrence rate of surgery alone is relatively high （22.3%）.